Company Overview

Cannabix Technologies Inc. is a Canada-based biotechnology company focused on the research, development, and commercialization of marijuana breathalyzer technologies. The company operates at the intersection of biotechnology, public safety, and law enforcement technology, with a primary emphasis on detecting recent cannabis consumption through breath analysis rather than impairment inference from blood or urine tests. Its core objective is to provide a non-invasive, rapid testing solution for use by law enforcement agencies, employers, and regulatory authorities.

The company’s principal product initiative is the Cannabix Marijuana Breathalyzer, which is designed to detect delta-9 tetrahydrocannabinol (THC) at trace levels in human breath. Cannabix Technologies Inc. was incorporated in Canada in 2004 and originally pursued alternative technology ventures before pivoting toward cannabis detection technologies following global cannabis legalization trends. Its strategic positioning is centered on intellectual property development and regulatory-aligned innovation in a niche but growing enforcement and compliance market.

Business Operations

Cannabix Technologies Inc. operates primarily through a single reporting business segment focused on breath-based THC detection technology development. Revenue generation to date has been minimal, as the company remains in the research and development stage and has not yet commercialized a mass-market product. Operations are largely funded through equity financing, consistent with early-stage technology development companies.

The company’s assets include internally developed intellectual property, laboratory testing equipment, and prototype breathalyzer devices. Research and development activities are conducted in Canada, with external laboratory collaborations used for validation and testing. Public disclosures indicate no material operating subsidiaries or revenue-generating joint ventures; the company operates as a standalone entity with a focus on proprietary technology advancement rather than diversified operations. Data inconclusive based on available public sources regarding any active long-term commercial partnerships.

Strategic Position & Investments

Cannabix Technologies Inc.’s strategic direction centers on advancing its THC Breathalyzer intellectual property portfolio, securing patents, and achieving technical milestones required for regulatory and law enforcement adoption. The company has publicly emphasized product miniaturization, sensitivity improvements, and real-time detection accuracy as key development goals.

Investment activity has primarily involved internal R&D spending rather than external acquisitions. There is no verified evidence of completed acquisitions or equity stakes in other operating companies based on public filings. Cannabix is positioned to benefit from evolving impaired-driving regulations in North America and other legalized cannabis markets, though commercialization timelines remain uncertain. Data inconclusive based on available public sources regarding definitive regulatory approvals or finalized supply agreements.

Geographic Footprint

Cannabix Technologies Inc. is headquartered in Canada, with its primary operational and research activities conducted domestically. The company’s public filings indicate that the majority of expenditures relate to Canadian-based research, patent filings, and administrative functions.

While the company references potential applicability of its technology in North America, Europe, and other international jurisdictions with legalized cannabis frameworks, it does not currently report material international operations or foreign revenue. Its geographic footprint is therefore best characterized as Canada-centric with an outward-facing strategic market focus rather than established global operations.

Leadership & Governance

Cannabix Technologies Inc. is governed by a board of directors and executive leadership team with experience in technology development, engineering, and corporate management. Leadership has consistently articulated a strategy centered on scientific validation, patent protection, and alignment with law enforcement requirements rather than rapid commercialization.

Key executives include:

• Rav Mlait – Chief Executive Officer
• Kal Malhi – Director
• Garry Johnson – Director
• Marcello Iannuzzelli – Chief Financial Officer

The leadership philosophy emphasizes disciplined research progression, intellectual property defensibility, and long-term value creation through regulatory-aligned innovation.